Total Assets (Quarterly) Chart

View Total Assets (Quarterly) for KALA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Assets (Quarterly) Chart
Start Trial

Historical Total Assets (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 10.58M
March 31, 2026 12.32M
December 31, 2025 9.49M
September 30, 2025 25.02M
June 30, 2025 36.05M
March 31, 2025 48.25M
December 31, 2024 55.48M
September 30, 2024 54.08M
June 30, 2024 61.61M
March 31, 2024 53.03M
December 31, 2023 55.95M
September 30, 2023 61.12M
June 30, 2023 66.50M
March 31, 2023 72.23M
December 31, 2022 86.82M
September 30, 2022 85.70M
June 30, 2022 84.98M
March 31, 2022 111.57M
December 31, 2021 139.43M
September 30, 2021 193.81M
June 30, 2021 215.46M
March 31, 2021 229.83M
December 31, 2020 221.61M
September 30, 2020 225.10M
Date Value
June 30, 2020 245.51M
March 31, 2020 258.53M
December 31, 2019 154.32M
September 30, 2019 161.01M
June 30, 2019 178.82M
March 31, 2019 197.02M
December 31, 2018 220.97M
September 30, 2018 84.08M
June 30, 2018 95.59M
March 31, 2018 104.99M
December 31, 2017 116.13M
September 30, 2017 123.69M
June 30, 2017 28.59M
March 31, 2017 37.61M
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
December 31, 2015 8.448M
September 30, 2015 12.65M
June 30, 2015
March 31, 2015
December 31, 2014 11.72M

Total Assets Definition

Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.

Read full definition.

Total Assets (Quarterly) Range, Past 5 Years

View Total Assets (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Assets (Quarterly) Benchmarks

View Total Assets (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.743B
Alnylam Pharmaceuticals, Inc. 5.559B
Anika Therapeutics, Inc. 183.47M
Savara, Inc. 192.14M
Vericel Corp. 502.87M

Total Assets (Quarterly) Related Metrics